Uncategorized

FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)

todayJanuary 21, 2025 329 49 4

Background
share close

Spravato, the brand name for esketamine, has a newly approved indication for treatment-resistant depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

(Image credit: tadamichi/Getty Images/iStockphoto)

Written by: Prometheus

Rate it

Listen

Our radio is always online!
Listen now completely free!
Email us to ADVERTISE

Based in and Broadcasting from Central New York in the USA  

We Are CNY’s   NEW BREW of Rock Station

Flip us on, and flip everyone else off

ASCAP License Number 400012286 

Central New York’s Rock Revolution!